Prana Biotechnology (NASDAQ:PRAN) was downgraded by MLV & Co. from a “buy” rating to a “hold” rating in a research note issued on Monday, Analyst Ratings Network reports. They currently have a $3.00 price target on the stock, down from their previous price target of $11.00. MLV & Co.‘s price target suggests a potential upside of 30.43% from the company’s current price. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares after opening at $1.39 on last trade day and at the end of the day closed at $1.85. Company price to sales ratio in past twelve months was calculated as 263.44 and price to cash ratio as 4.52. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) showed a negative weekly performance of -20.26%.
On Mar 27, 2014 Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) announced that Threshold’s partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has initiated a Phase 1 dose escalation study assessing the safety, tolerability and anti-tumor activity of the investigational hypoxia-targeted drug TH-302 in combination with gemcitabine and nab-paclitaxel (Abraxane(R) ) in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) shares fell -6.47% in last trading session and ended the day on $4.05. THLD return on equity ratio is recorded as 129.10% and its return on assets is -26.80%. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) yearly performance is -12.72%.
On April 8, 2014 Curis, Inc. (NASDAQ:CRIS) announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in Phase 1 trial in combination with everolimus, a mTOR inhibitor in advanced RCC patients. Curis, Inc. (NASDAQ:CRIS) shares moved down -5.58% in last trading session and was closed at $2.37, while trading in range of $2.36 – $2.60. Curis, Inc. (NASDAQ:CRIS) year to date (YTD) performance is -15.96%.
Gevo (NASDAQ:GEVO) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday, Analyst Ratings.Net reports. The firm currently has a $1.50 price objective on the stock. Zacks‘s target price suggests a potential upside of 31.58% from the stock’s previous close. Gevo, Inc. (NASDAQ:GEVO) weekly performance is -5.51%. On last trading day company shares ended up $1.12. Gevo, Inc. (NASDAQ:GEVO) distance from 50-day simple moving average (SMA50) is -13.82%. Analysts mean target price for the company is $ 4.21.